WuXi Biologics Announces Record-Breaking Financial Performance for Fiscal Year 2025
WuXi Biologics has reported a year of strong financial performance and operational expansion for the fiscal year ending December 31, 2025, underscoring its growing influence as a leading global contract research, development, and manufacturing organization (CRDMO) in the biologics sector. The company’s audited results highlight not only robust revenue growth and profitability improvements but also significant advancements across its integrated research, development, and manufacturing (R-D-M) platform, reinforcing its long-term growth trajectory.
Strong Financial Performance Reflecting Strategic Execution
WuXi Biologics delivered impressive financial results during the reporting period, driven by its well-established “Follow and Win the Molecule” strategy and increasing global demand for advanced biologics. Total revenue rose by 16.7% year-over-year to RMB 21.8 billion, reflecting sustained momentum across its diversified service offerings. Growth was fueled by rising demand for complex biologics modalities such as bispecific antibodies and antibody-drug conjugates (ADCs), alongside increased engagement in research partnerships and improved utilization of its global manufacturing capacity, including contributions from its expanding European operations.
Profitability also improved significantly. Gross profit under IFRS increased by 30.9% to RMB 10.0 billion, with gross margin expanding by 500 basis points to 46.0%. On an adjusted basis, gross profit reached RMB 10.6 billion, with margins climbing to 48.8%. These gains were primarily attributed to a favorable business mix, higher capacity utilization, and efficiency enhancements driven by the WuXi Biologics Business System (WBS) and digital transformation initiatives.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) surged by 38.1% to RMB 9.0 billion, while adjusted EBITDA grew by 22.8% to RMB 9.8 billion. EBITDA margins reached 41.5%, with adjusted margins rising to 45.1%, reflecting strong operational leverage. Net profit also saw substantial growth, increasing by 45.3% to RMB 5.7 billion, while profit attributable to shareholders rose by 46.3% to RMB 4.9 billion. Adjusted net profit reached RMB 6.6 billion, demonstrating consistent underlying performance.
Earnings per share (EPS) mirrored this upward trend, with basic EPS rising nearly 49% to RMB 1.22 and diluted EPS increasing to RMB 1.16. Adjusted EPS also posted solid gains, reflecting the company’s ability to translate operational success into shareholder value.
Expanding Pipeline and Project Momentum
A key driver of WuXi Biologics’ growth in 2025 was the expansion of its project pipeline. The company added a record 209 new integrated projects during the year, bringing its total pipeline to 945 programs. Approximately half of these new projects originated from U.S.-based clients, highlighting strong demand from the global biopharmaceutical industry, particularly in North America.
The company’s “Win-the-Molecule” strategy continued to deliver results, with 23 post-investigational new drug (IND) projects secured during the year, including six late-stage programs. Since 2018, WuXi Biologics has accumulated 112 such projects, demonstrating its ability to retain and advance client molecules through the development lifecycle.
The pipeline includes 74 late-stage projects and 25 commercial-stage programs, providing a solid foundation for future manufacturing revenue growth. This progression reflects the company’s ability to convert early-stage collaborations into long-term commercial partnerships.
Research Services Driving High-Value Opportunities
WuXi Biologics’ Research Services segment achieved another record year, generating significant upfront payments and securing potential milestone and royalty revenues exceeding US$4 billion. The company’s CD3 T-cell engager (TCE) platform continued to gain traction, with partnerships expanding among leading biopharmaceutical companies such as Vertex Pharmaceuticals, Merck, GSK, and Sino Biopharmaceutical.
By the end of 2025, the Research Services division was supporting more than 50 active programs eligible for milestone payments and royalties, creating a growing base of high-margin, long-term revenue streams.
Development Capabilities Advancing Complex Modalities
The company’s development segment also saw substantial progress, supporting 156 IND filings during the year. WuXi Biologics expanded its regulatory submission capacity to handle approximately 200 INDs and 20 biologics license applications (BLAs) or marketing authorization applications (MAAs) annually.
Notably, complex biologics such as bispecific antibodies and ADCs accounted for two-thirds of new development projects, with both categories experiencing approximately 30% growth. These modalities now represent more than half of the company’s total project portfolio, highlighting a broader industry shift toward next-generation biologics and WuXi Biologics’ leadership in this space.
Bi- and multi-specific biologics emerged as the fastest-growing segment, contributing nearly 20% of total revenue and achieving over 120% year-over-year growth. To support this expansion, the company introduced WuXia™ TrueSite, an advanced cell line development platform designed to accelerate timelines from DNA to IND to approximately six months while maintaining high expression stability and productivity.
Additionally, WuXi Biologics enhanced its drug delivery capabilities, including high-throughput formulation technologies, co-formulation strategies, and large-volume delivery systems. These innovations expand the company’s ability to support both clinical and commercial applications across diverse therapeutic areas.
Manufacturing Excellence and Global Expansion
Manufacturing remained a cornerstone of WuXi Biologics’ operations, with the company supporting 74 Phase III projects and 25 commercial manufacturing programs in 2025. It completed 28 process performance qualification (PPQ) campaigns with a 100% success rate, demonstrating consistent execution and high-quality standards. Looking ahead, 34 PPQs are already scheduled for 2026, providing strong visibility into future revenue growth.
To support its expanding pipeline and ensure supply chain resilience, WuXi Biologics continued to invest in its global manufacturing footprint. In the United States, construction of a new facility in Worcester, Massachusetts, is progressing, while upgrades in Cranbury, New Jersey, aim to enhance commercial manufacturing capabilities.
In Singapore, the company has begun building a large modular drug product facility, expected to be one of the largest of its kind globally. Plans are also underway for a modular drug substance facility in the region. Meanwhile, a memorandum of understanding signed with the Qatar Free Zones Authority marks the company’s entry into the Middle East, further extending its global reach.
Strong Backlog and Quality Track Record
WuXi Biologics ended 2025 with a total backlog of US$23.7 billion, including US$11.5 billion in service backlog and US$12.2 billion in potential milestone payments. Of this, US$4.5 billion is expected to be realized within three years, providing strong revenue visibility.
The company’s commitment to quality remains a key differentiator. Between 2017 and 2025, it completed 46 regulatory inspections by major global authorities, including 22 by the U.S. FDA and EU EMA, with no critical findings. It also maintained a 100% pass rate for FDA pre-license inspections and successfully completed over 1,800 client GMP audits.
Talent, Digitalization, and Sustainability
As of the end of 2025, WuXi Biologics employed more than 13,000 staff globally, including nearly 5,000 scientists, with a strong retention rate of 96.4%. Operational efficiency continued to improve through the WBS framework, with over 430 process improvement initiatives contributing to margin expansion.
Digitalization also played a critical role, with advanced tools such as electronic batch records, manufacturing execution systems, and digital twin technologies enhancing productivity and quality across operations.
The company also strengthened its sustainability credentials, earning recognition from major ESG rating agencies and inclusion in leading sustainability indices.
Leadership Perspective and Future Outlook
Chris Chen highlighted the company’s strong execution across its integrated platform, emphasizing the role of advanced biologics and operational efficiencies in driving growth. Meanwhile, Ge Li reaffirmed the company’s commitment to innovation and long-term value creation.
Looking ahead, WuXi Biologics plans to continue expanding its global CRDMO network, investing in advanced technologies, and strengthening its integrated capabilities. With a robust pipeline, strong backlog, and expanding global footprint, the company is well-positioned to support the evolving needs of the biopharmaceutical industry and sustain its growth momentum in the years to come.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
Source Link: https://www.wuxibiologics.com/
